Related Experiment Video

Updated: Oct 29, 2025

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.8K

The Role of Antisense Therapies Targeting Lipoprotein(a)

Roda Plakogiannis1, Maria Sorbera1, Briann Fischetti1

  • 1Department of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York; and.

Journal of Cardiovascular Pharmacology
|July 7, 2021
PubMed

Insights

Elevated lipoprotein(a) [Lp(a)] is a key predictor of cardiovascular risk. New therapies, like antisense oligonucleotides, show promise in lowering Lp(a) and reducing residual cardiovascular risk in high-risk patients.

Area of Science:

  • Cardiovascular Medicine
  • Lipidology
  • Pharmacology

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of preventable death.
  • Elevated low-density lipoprotein cholesterol (LDL-C) contributes significantly to ASCVD.
  • Residual cardiovascular risk persists despite effective LDL-C lowering therapies.

Purpose of the Study:

  • To highlight lipoprotein(a) [Lp(a)] as an independent predictor of ASCVD.
  • To explore the potential of reducing Lp(a) levels to mitigate residual cardiovascular risk.
  • To review current and emerging therapeutic strategies for Lp(a) lowering.

Main Methods:

  • Review of existing literature on Lp(a) and cardiovascular disease.
  • Discussion of pharmacological agents targeting Lp(a) reduction, including nicotinic acid, PCSK9 inhibitors, and antisense oligonucleotides.
  • Focus on the role of antisense oligonucleotides, specifically APO(a)LRx, in lowering Lp(a).

Main Results:

  • Elevated Lp(a) is an inherent, independent predictor of ASCVD.
  • No approved medications currently exist specifically to lower Lp(a).
  • Several agents, including antisense oligonucleotides, demonstrate potential for Lp(a) reduction.

Conclusions:

  • Decreasing Lp(a) levels may significantly reduce residual cardiovascular risk in high-risk individuals.
  • APO(a)LRx is a leading candidate for selective Lp(a) lowering.
  • Further research is needed to confirm the cardiovascular benefits of Lp(a)-mediated risk reduction.

More Related Videos

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.7K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
84
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.0K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.4K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.6K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
86
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
274